Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;20(2):538-545.
doi: 10.1111/ajt.15592. Epub 2019 Oct 3.

Deletion of donor-reactive T cell clones after human liver transplant

Affiliations

Deletion of donor-reactive T cell clones after human liver transplant

Thomas M Savage et al. Am J Transplant. 2020 Feb.

Abstract

We recently developed a high throughput T cell receptor β chain (TCRβ) sequencing-based approach to identifying and tracking donor-reactive T cells. To address the role of clonal deletion in liver allograft tolerance, we applied this method in samples from a recent randomized study, ITN030ST, in which immunosuppression withdrawal was attempted within 2 years of liver transplantation. We identified donor-reactive T cell clones via TCRβ sequencing following a pre-transplant mixed lymphocyte reaction and tracked these clones in the circulation following transplantation in 3 tolerant and 5 non-tolerant subjects. All subjects showed a downward trend and significant reductions in donor-reactive TCRβ sequences were detected post-transplant in 6 of 8 subjects, including 2 tolerant and 4 non-tolerant recipients. Reductions in donor-reactive TCRβ sequences were greater than those of all other TCRβ sequences, including 3rd party-reactive sequences, in all 8 subjects, demonstrating an impact of the liver allograft after accounting for repertoire turnover. Although limited by patient number and heterogeneity, our results suggest that partial deletion of donor-reactive T cell clones may be a consequence of liver transplantation and does not correlate with success or failure of early immunosuppression withdrawal. These observations underscore the organ- and/or protocol-specific nature of tolerance mechanisms in humans.

Keywords: T cell biology; basic (laboratory) research/science; immunobiology; liver transplantation/hepatology; monitoring: immune; tolerance.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE

The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. H.R. owns stock in Adaptive Biotechnologies, Inc. The other authors have no conflicts of interest to disclose

Figures

Fig. 1.
Fig. 1.. Study design.
(A) Schematic of subjects in ITN030ST study randomized to immunosuppression withdrawal. Tolerant subjects diagrammed on left and non-tolerant subjects on right. Key time points shown at top and sample collection at bottom. (B) Schematic of identification and tracking of the donor-reactive TCRβ repertoire via the pre-transplant CFSE-MLR.
Fig. 2.
Fig. 2.. Reduction in detection of donor-reactive TCRβ sequences after liver transplantation.
Counts of donor-reactive TCRβ sequences in pre- and post-transplant CD4 and CD8 samples with ≥90% detection power for (A) tolerant and (B) non-tolerant non-immune, non-viral subjects, and for (C) tolerant and (D) non-tolerant HCV subjects. n corresponds to the number of total donor-reactive CD4 or CD8 sequences. Fold change in detection of donor-reactive sequences among (E) non-immune, non-viral subjects and (F) HCV subjects. Fold change is defined as the ratio of the odds of detecting donor-reactive sequences post-transplant relative to pre-transplant. Notation following each subject in the key refers to p-value at each time point pre-randomization/post-randomization. *p<0.05 reduction or increase in odds of detection of donor-reactive sequences compared to pre-transplant (two-sided Fisher’s exact test); tabulated data in Table S4.
Fig. 3.
Fig. 3.. Repertoire turnover post-transplant.
Jensen-Shannon-Divergence (JSD) comparing the top 1000 TCRβ sequences at each post-transplant time point to the top 1000 TCRβ sequences pre-transplant for (A) non-immune, non-viral subjects and (B) HCV subjects. JSD ranges from 0 to 1, with 1 representing complete divergence and 0 representing identical samples.
Fig. 4.
Fig. 4.. Reduced detection of donor-reactive sequences after accounting for repertoire turnover.
Relative change in detection of donor-reactive TCRβ sequences for (A) non-immune, non-viral subjects and (B) HCV subjects, where black are tolerant and red are non-tolerant subjects. Relative change at a post-transplant time-point is the ratio of the odds of detecting pre-transplant-identified donor-reactive sequences to the odds of detecting any pre-transplant-identified (unstimulated) sequences at the same post-transplant timepoint. A value of 1 indicates that the proportion of pre-transplant-identified donor-reactive sequences detected at a given time point was equal to that for any pre-transplant-identified sequences. Values <1 and >1 indicate a lower rate and a greater rate, respectively, of detection of donor-reactive versus any pre-transplant sequences. Notation following each subject in the key refers to p-value for each time point pre-randomization/post-randomization. *p<0.05 reduction or increase in odds of post-transplant detection of pre-transplant-identified donor-reactive sequences compared to unstimulated pre-transplant sequences (two-sided Fisher’s exact test); tabulated data in Table S5.
Figure 5.
Figure 5.. Reduced detection of donor-reactive relative to 3rd party-reactive TCRβ sequences.
At pre-randomization and post-randomization time points, comparison of (A) fold change in detection of donor-reactive sequences to fold change in detection of 3rd party-reactive sequences and (B) change in detection relative to pre-transplant unstimulated sequences of donor-reactive sequences compared to 3rd party-reactive sequences. *p<0.05, **p<0.01, p-value calculated from two-sided paired t-test.

Similar articles

Cited by

References

    1. Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA. 2012;307(3):283–293. - PubMed
    1. Benitez C, Londono MC, Miquel R, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology. 2013;58(5):1824–1835. - PubMed
    1. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 1992;103(1):317–322. - PubMed
    1. Tisone G, Orlando G, Cardillo A, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol. 2006;44(4):702–709. - PubMed
    1. Qian S, Demetris AJ, Murase N, Rao AS, Fung JJ, Starzl TE. Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology. 1994;19(4):916–924. - PMC - PubMed

Publication types

MeSH terms